BC Extra | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In...
BC Week In Review | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
BC Extra | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Nov 3, 2017
Regulation

Frame work

A little over four years into its implementation, FDA’s structured benefit-risk framework appears to be meeting its objectives of creating transparency into its approval decisions. The agency began to incorporate the framework templates into its...
BC Extra | Jul 11, 2017
Clinical News

Arena rises after hours on Phase II PAH data

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) jumped $7.60 (41%) to $25.99 in after-hours trading Monday after it said ralinepag ( APD811 ) significantly improved absolute change from baseline in pulmonary vascular resistance (PVR) in a Phase II trial to...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BC Week In Review | Apr 14, 2017
Clinical News

Uptravi regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) completed a safety review of Alexion's Uptravi selexipag, concluding that the "data examined do not suggest any increase in mortality" with the pulmonary arterial hypertension (PAH) drug. PRAC initiated...
BioCentury | Feb 4, 2017
Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...
BC Week In Review | Jan 27, 2017
Company News

J&J, Actelion deal

Johnson & Johnson will acquire Actelion for $280 per share in cash, or about $30 billion. Based on current exchange rates, the price is a 23% premium to Actelion's closing price of CHF227.40 on Jan....
Items per page:
1 - 10 of 70